标题：Trend of Histone Deacetylase Inhibitors in Cancer Therapy: Isoform Selectivity or Multitargeted Strategy
作者：Zhang, Lei;Han, Yantao;Jiang, Qixiao;Wang, Chunbo;Chen, Xuehong;Li, Xiaoguang;Xu, Fuming;Jiang, Yuqi;Wang, Qiang;Xu, Wenfang
作者机构：[Zhang, L] Department of Medicinal Chemistry, School of Pharmacy, Qingdao University, Qingdao, Shandong, China;[ Han, Y] Department of Medicinal Chemi 更多
通讯作者地址：[Zhang, L]Qingdao Univ, Sch Pharm, Dept Med Chem, Qingdao 266071, Shandong, Peoples R China.
来源：Medicinal research reviews
关键词：histone deacetylase;inhibitors;selectivity;multitargeted;bifunctional molecule
摘要：Pharmacological inhibition of histone deacetylases (HDACs) has been successfully applied in the treatment of a wide range of disorders, including Parkinson\'s disease, infection, cardiac diseases, inflammation, and especially cancer. HDAC inhibitors (HDACIs) have been proved to be effective antitumor agents by various stages of investigation. At present, there are two opposite focuses of HDACI design in the cancer therapy, highly selective inhibitor strategy and dual- or multitargeted inhibitors. The former method, which is supposed to elucidate the function of individual HDAC and provide candidate inhibitors with fewer side effects, has been widely accepted by the inhibitor developer. The latter approach, though less practiced, has promising potential for the antitumor therapy based on HDACIs. Effective HDACIs, some of which are in clinic anticancer research, have been developed by both methods. In order to gain insight into HDACI design, the strategies and achievements of the two diverse methods are reviewed.